Navigation Links
Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
Date:5/21/2010

) were noted in two of five patients with head and neck cancer. The Phase 2 study treated head and neck cancer patients at the maximum dose level (3 x 10(10) TCID(50)) in order to further assess tumour response. In total, 19 patients with head and neck cancer received at least two cycles and are evaluable for response. Most were SCCHN refractory to previous platinum-based chemotherapy for recurrent/metastatic disease. PR was seen in eight patients (42%) and stable disease (SD) in six (32%). One additional PR and one SD were observed among four patients with malignant melanoma. The researchers expect final results for median overall survival (OS) and progression free survival (PFS) will be presented.

The researchers concluded that intravenous administration of reovirus in combination with carboplatin/paclitaxel is a safe and well-tolerated combination with promising anticancer activity in SCCHN. Further evaluation of this combination in a randomized Phase III trial in SCCHN is underway. The poster is expected to be presented in a session on Monday June 7, 2010 from 8:00 am to 12:00 pm CDT.

The second abstract entitled "Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors," covers a poster presentation relating to the structure of the Company's REO 016 trial. The poster is expected to be presented in a session on Monday June 7, 2010 from 8:00 am to 12:00 pm CDT.

The third abstract entitled "Phase I/II trial of reovirus serotype 3-Dearing strain in patients with recurrent ovarian cancer," covers a poster presentation relating to the structure of a National Cancer Institute (NCI) sponsored study for patients with metastatic ovarian, peritoneal and fallopian tube cancers using concurrent intravenous and
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
2. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
3. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
4. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
5. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
6. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
7. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
8. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
9. Oncolytics Biotech(R) Inc. Announces Unit Offering
10. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
11. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 Research and Markets ... N-acetylcysteine Industry Report 2014" report to their ... Report 2014 is a professional and in-depth study ... industry. The report provides a basic ... and industry chain structure. The N-acetylcysteine market analysis ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - ... offering. The global companion diagnostics market ... from 2014 to 2019. Factors such as rising need ... companion diagnostics by the pharmaceutical industry, support from regulatory ...
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... an exclusive license for technology developed by the ... expression in plants, including for applications in production of ... The technology was developed under the direction of ... Kultevat and former president of the Danforth Plant Science ...
(Date:9/18/2014)... Ky. , Sept. 18, 2014  Neogen Corporation ... has entered into a strategic agreement with Merck Animal ... Program. The Igenity Dairy Heifer Program ... essential information on the genetic potential of replacement dairy ... a calf is born, and is an excellent tool ...
Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Kultevat obtains license of gene switch technology 2Merck Animal Health to market Neogen's dairy genomic program 2
... PHOENIX, Nov. 10, 2011 Wolters Kluwer Pharma ... is providing its industry research and analytics to investors ... distribution is managed by in ... business, which specializes in forward-looking analyses of pharmaceutical drugs ...
... SAN DIEGO, Nov. 10, 2011 Sequenom, Inc. (NASDAQ: ... analysis solutions, today announced the Company,s participation at the Lazard ... in New York City November 15-16, 2011. Harry ... Lindsay, Ph.D., Director and EVP of Research and Development, will ...
... material that absorbs on average more than 99 percent ... hits it -- a development that promises to open ... engineers at NASA,s Goddard Space Flight Center in Greenbelt, ... and Photonics conference, the largest interdisciplinary technical meeting in ...
Cached Biology Technology:Wolters Kluwer Research Now Available via Bloomberg Tradebook 2Wolters Kluwer Research Now Available via Bloomberg Tradebook 3Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference 2NASA develops super-black material that absorbs light across multiple wavelength bands 2NASA develops super-black material that absorbs light across multiple wavelength bands 3
(Date:9/18/2014)... a world-leading provider of scientific, technical and medical ... Management Society (ARMS), recognized the academic research achievements ... Young Researcher of the Year Awards. , The ... Convention Centre and in conjunction with the ARMS ... Australia,s and New Zealand,s scientific community. Guest of ...
(Date:9/18/2014)... entire lives nestling in the protective tentacles of host ... sometimes travel hundreds of kilometres across the open ocean. ... has been predicted, this is the first time that ... has been observed. , Dr Steve Simpson, Senior Lecturer ... of Exeter, and colleagues from the Australian Research Council ...
(Date:9/17/2014)... Fauna Europaea started in 2000 as an EC-FP5 four-year ... years of steady progress and successful participations in several ... European Biodiversity Observation Network project (EU BON), to ... the contributors and to extend the general dissemination of ... Journal has applied its novel e-Publishing tools ...
Breaking Biology News(10 mins):Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... Researchers are delving into abnormal gene function in mitochondria, ... the place where energy is generated from the most ... to life, defects in mitochondria may affect a wide ... Some names of mitochondrial disorders are Leigh,s disease, ...
... research, published this week in Chemical Communications , ... insects, ability to detect plants by interfering with their ... by insect pests and contribute to food security. ... institute of BBSRC said: "One way in which insects ...
... that a University of Utah cardiologist proposes as a cause ... National Institutes of Health (NIH) likes to seeand reward with ... Pioneer Award. Ivor J. Benjamin, M.D., professor of internal ... of Cardiovascular Research at the U of U School of ...
Cached Biology News:How mitochondrial gene defects impair respiration, other major life functions 2How mitochondrial gene defects impair respiration, other major life functions 3Scientists discover how to send insects off the scent of crops 2Groundbreaking model of heart disease rewarded with NIH Pioneer Award 2Groundbreaking model of heart disease rewarded with NIH Pioneer Award 3